Shedir Pharma Srl Unipersonale
MIL:SHE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sitoy Group Holdings Ltd
HKEX:1023
|
HK |
Shedir Pharma Srl Unipersonale
Total Current Assets
Shedir Pharma Srl Unipersonale
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shedir Pharma Srl Unipersonale
MIL:SHE
|
Total Current Assets
€41.9m
|
CAGR 3-Years
1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Newron Pharmaceuticals SpA
SIX:NWRN
|
Total Current Assets
€38.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
|
Total Current Assets
€1.7B
|
CAGR 3-Years
13%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
Shedir Pharma Srl Unipersonale
Glance View
Shedir Pharma Group SpA operates as a holding company which engages in the research and development of nutraceuticals and medical devices. The company is headquartered in Mercato San Severino, Salerno and currently employs 71 full-time employees. The company went IPO on 2019-07-23. The firm markets its products in different forms and under the brand lines Shedir Farmaceutici, Deimos Farmaceutici, Phobos Farmaceutici, Menkar Farmaceutici and Greenplanet Divisione Farmaceutica. Its products cover a wide range of therapeutics areas, such as cardiovascular, dermatology, neurology, urology, gynecology and dental health, among others.
See Also
What is Shedir Pharma Srl Unipersonale's Total Current Assets?
Total Current Assets
41.9m
EUR
Based on the financial report for Dec 31, 2023, Shedir Pharma Srl Unipersonale's Total Current Assets amounts to 41.9m EUR.
What is Shedir Pharma Srl Unipersonale's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
6%
Over the last year, the Total Current Assets growth was -5%. The average annual Total Current Assets growth rates for Shedir Pharma Srl Unipersonale have been 1% over the past three years , 6% over the past five years .
